FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1911366939> ?p ?o ?g. }

• W1911366939 abstract "Background Chronic lung disease (CLD) remains a major problem in neonatal intensive care units. Persistent inflammation in the lungs is the most likely underlying pathogenesis. Corticosteroids have been used to either prevent or treat CLD because of their potent anti‐inflammatory effects. Objectives To determine if postnatal corticosteroid treatment is of benefit in the prevention of chronic lung disease (CLD) in preterm infants. This review examines the outcome of trials where preterm infants at risk of CLD were given postnatal corticosteroids within the first seven days of life. Search methods Randomised controlled trials (RCTs) of postnatal corticosteroid therapy were sought from the Cochrane Controlled Trials Register, MEDLINE (1966 ‐ May 2008), hand searching paediatric and perinatal journals, examining previous review articles and information received from practising neonatologists. Authors of all studies were contacted, where possible, to confirm details of reported follow‐up studies, or to obtain any information about long‐term follow‐up where none had been reported. Selection criteria Randomised controlled trials of postnatal corticosteroid treatment within the first 7 days of life (early) in high risk preterm infants were selected for this review. Most studies evaluated the use of dexamethasone but we also included studies that assessed hydrocortisone, even if it was used to manage hypotension. Data collection and analysis Data regarding clinical outcomes including mortality, CLD (including late rescue with corticosteroids, and need for home oxygen therapy), death or CLD, failure to extubate, complications during the primary hospitalisation (including infection, hyperglycaemia, hypertension, pulmonary air leak, patent ductus arteriosus (PDA), severe intraventricular haemorrhage (IVH), periventricular leucomalacia (PVL), necrotising enterocolitis (NEC), gastrointestinal bleeding, intestinal perforation, severe retinopathy of prematurity (ROP), and long‐term outcome (including blindness, deafness, cerebral palsy and major neurosensory disability) were abstracted and analysed using RevMan 5. Main results Twenty‐eight RCTs enrolling a total of 3740 participants were eligible for inclusion in this review. A meta‐analysis of these trials demonstrated significant benefits as regards earlier extubation and decreased risks of CLD at both 28 days and 36 weeks' postmenstrual age (PMA), death or CLD at 28 days and 36 weeks' PMA, PDA and ROP, including severe ROP. There were no significant differences in the rates of neonatal or subsequent mortality, infection, severe IVH, PVL, NEC or pulmonary haemorrhage. Gastrointestinal bleeding and intestinal perforation were important adverse effects and the risks of hyperglycaemia, hypertension, hypertrophic cardiomyopathy and growth failure were also increased. In the twelve trials that reported late outcomes, several adverse neurological effects were found at follow‐up examinations including developmental delay (not defined), cerebral palsy and abnormal neurological examination. However, major neurosensory disability was not significantly increased, either overall in the seven studies where this outcome could be determined, or in the two individual studies where the rates of cerebral palsy or abnormal neurological examination were significantly increased. Moreover, the rates of the combined outcomes of death or cerebral palsy, or of death or major neurosensory disability were not significantly increased. Dexamethasone was the drug used in most studies (n = 20); only eight studies used hydrocortisone. In subgroup analyses by type of corticosteroid, most of the beneficial and harmful effects were attributable to dexamethasone; hydrocortisone had little effect on any outcomes except for an increase in intestinal perforation and a borderline reduction in PDA. Authors' conclusions The benefits of early postnatal corticosteroid treatment (≤ 7 days), particularly dexamethasone, may not outweigh the known or potential adverse effects of this treatment. Although early corticosteroid treatment facilitates extubation and reduces the risk of chronic lung disease and patent ductus arteriosus, it causes short‐term adverse effects including gastrointestinal bleeding, intestinal perforation, hyperglycaemia, hypertension, hypertrophic cardiomyopathy and growth failure. Long‐term follow‐up studies report an increased risk of abnormal neurological examination and cerebral palsy. However, the methodological quality of the studies determining long‐term outcomes is limited in some cases; the surviving children have been assessed predominantly before school age, and no study has been sufficiently powered to detect important adverse long‐term neurosensory outcomes. There is a compelling need for the long‐term follow‐up and reporting of late outcomes, especially neurological and developmental outcomes, among surviving infants who participated in all randomised trials of early postnatal corticosteroid treatment. Hydrocortisone in the doses and regimens used in the reported RCTs has few beneficial or harmful effects and cannot be recommended for prevention of CLD." @default.
• W1911366939 created "2016-06-24" @default.
• W1911366939 creator A5063657135 @default.
• W1911366939 creator A5065325564 @default.
• W1911366939 creator A5080368882 @default.
• W1911366939 date "2009-01-21" @default.
• W1911366939 modified "2023-10-10" @default.
• W1911366939 title "Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants" @default.
• W1911366939 cites W105945747 @default.
• W1911366939 cites W1555431179 @default.
• W1911366939 cites W1678401570 @default.
• W1911366939 cites W1918735157 @default.
• W1911366939 cites W1960244799 @default.
• W1911366939 cites W1963560842 @default.
• W1911366939 cites W1966346251 @default.
• W1911366939 cites W1967369006 @default.
• W1911366939 cites W1971024627 @default.
• W1911366939 cites W1974396702 @default.
• W1911366939 cites W1975024285 @default.
• W1911366939 cites W1979889758 @default.
• W1911366939 cites W1983302188 @default.
• W1911366939 cites W1985860056 @default.
• W1911366939 cites W1986180694 @default.
• W1911366939 cites W1986347575 @default.
• W1911366939 cites W1994731787 @default.
• W1911366939 cites W1996760285 @default.
• W1911366939 cites W1996914834 @default.
• W1911366939 cites W1999704974 @default.
• W1911366939 cites W2002526952 @default.
• W1911366939 cites W2006568346 @default.
• W1911366939 cites W2010045713 @default.
• W1911366939 cites W2010803646 @default.
• W1911366939 cites W2012271480 @default.
• W1911366939 cites W2013796379 @default.
• W1911366939 cites W2014273178 @default.
• W1911366939 cites W2014830091 @default.
• W1911366939 cites W2019186323 @default.
• W1911366939 cites W2020524106 @default.
• W1911366939 cites W2024503023 @default.
• W1911366939 cites W2024557249 @default.
• W1911366939 cites W2029776119 @default.
• W1911366939 cites W2043614863 @default.
• W1911366939 cites W2044071421 @default.
• W1911366939 cites W2047860382 @default.
• W1911366939 cites W2050699728 @default.
• W1911366939 cites W2050781087 @default.
• W1911366939 cites W2051694049 @default.
• W1911366939 cites W2052188494 @default.
• W1911366939 cites W2052191146 @default.
• W1911366939 cites W2052543033 @default.
• W1911366939 cites W2052971975 @default.
• W1911366939 cites W2071340880 @default.
• W1911366939 cites W2073218746 @default.
• W1911366939 cites W2078629243 @default.
• W1911366939 cites W2081581080 @default.
• W1911366939 cites W2083570685 @default.
• W1911366939 cites W2085164725 @default.
• W1911366939 cites W2092852861 @default.
• W1911366939 cites W2093095193 @default.
• W1911366939 cites W2104637428 @default.
• W1911366939 cites W2110168836 @default.
• W1911366939 cites W2116618515 @default.
• W1911366939 cites W2127799076 @default.
• W1911366939 cites W2134586161 @default.
• W1911366939 cites W2136881786 @default.
• W1911366939 cites W2138666525 @default.
• W1911366939 cites W2141078013 @default.
• W1911366939 cites W2150432453 @default.
• W1911366939 cites W2150710006 @default.
• W1911366939 cites W2313210773 @default.
• W1911366939 cites W2317266832 @default.
• W1911366939 cites W4210858056 @default.
• W1911366939 cites W4251842027 @default.
• W1911366939 cites W4253577747 @default.
• W1911366939 doi "https://doi.org/10.1002/14651858.cd001146.pub2" @default.
• W1911366939 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24825456" @default.
• W1911366939 hasPublicationYear "2009" @default.
• W1911366939 type Work @default.
• W1911366939 sameAs 1911366939 @default.
• W1911366939 citedByCount "161" @default.
• W1911366939 countsByYear W19113669392012 @default.
• W1911366939 countsByYear W19113669392013 @default.
• W1911366939 countsByYear W19113669392014 @default.
• W1911366939 countsByYear W19113669392015 @default.
• W1911366939 countsByYear W19113669392016 @default.
• W1911366939 countsByYear W19113669392017 @default.
• W1911366939 countsByYear W19113669392018 @default.
• W1911366939 countsByYear W19113669392019 @default.
• W1911366939 countsByYear W19113669392020 @default.
• W1911366939 countsByYear W19113669392021 @default.
• W1911366939 countsByYear W19113669392022 @default.
• W1911366939 countsByYear W19113669392023 @default.
• W1911366939 crossrefType "reference-entry" @default.
• W1911366939 hasAuthorship W1911366939A5063657135 @default.
• W1911366939 hasAuthorship W1911366939A5065325564 @default.
• W1911366939 hasAuthorship W1911366939A5080368882 @default.
• W1911366939 hasConcept C126322002 @default.
• W1911366939 hasConcept C168563851 @default.
• W1911366939 hasConcept C177713679 @default.
• W1911366939 hasConcept C187212893 @default.

• next